19.12.2024 16:07 | SAR | Results of AGM | RNS |
19.12.2024 07:00 | SAR | AGM Statement | RNS |
18.12.2024 07:00 | SAR | Appointment of Joint Broker | RNS |
16.12.2024 07:00 | SAR | Award of Share Options | RNS |
12.12.2024 11:45 | RENX, SAR, PTEC | UK shareholder meetings calendar - next 7 days | Alliance |
27.11.2024 09:38 | SAR | Notice of AGM, Annual Report and Accounts | RNS |
29.10.2024 14:27 | SAR | Sareum annual loss widens as remains focused on autoimmune diseases | Alliance |
29.10.2024 07:00 | SAR | Final Results for the Year Ended 30 June 2024 | RNS |
23.10.2024 07:00 | SAR | Notice of Final Results and Investor Presentation | RNS |
21.10.2024 18:21 | SAR | IN BRIEF: Sareum raises further GBP1.0 million via subscription | Alliance |
11.10.2024 15:53 | SAR | Sareum Holdings completes GBP2.4 million fundraise to boost lead asset | Alliance |
11.10.2024 07:00 | SAR | Subscription to raise £2,364,000 | RNS |
16.09.2024 14:27 | SAR | Sareum receives patent allowance for crystalline SDC-1801 in China | Alliance |
16.09.2024 07:00 | SAR | Patent Allowance in China | RNS |
02.09.2024 07:00 | SAR | US patent allowance | RNS |
10.07.2024 11:10 | SAR | Sareum Co-Founder & CEO Tim Mitchell steps back after twenty years | Alliance |
10.07.2024 07:00 | SAR | Management Changes | RNS |
01.07.2024 11:09 | ECOR, RBW, ORR | TRADING UPDATES: Rainbow Rare and Ecora strike Phalaborwa deal | Alliance |
01.07.2024 07:00 | SAR | Positive Data from SDC-1801 Phase 1 Clinical Trial | RNS |
30.05.2024 07:00 | SAR | Appointment of Sole Broker | RNS |
07.05.2024 14:10 | SAR | Exercise of Warrants | RNS |
23.04.2024 07:00 | SAR | Final Issue of RiverFort Subscription Shares | RNS |
19.04.2024 12:16 | SAR | IN BRIEF: Sareum falls as issues shares to RiverFort Global | Alliance |
19.04.2024 11:35 | SAR | Issue of RiverFort Subscription Shares | RNS |
15.04.2024 15:28 | SAR | Issue of RiverFort Subscription Shares | RNS |
09.04.2024 16:00 | SAR | Issue of RiverFort Subscription Shares | RNS |
04.04.2024 17:24 | SBSI, SAR, CODE | TRADING UPDATES: Northcoders launches bootcamp; Schroder invests | Alliance |
04.04.2024 14:38 | SAR | Completion of Equity Fundraise | RNS |
02.04.2024 17:35 | NOG, XLM, RGT | TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec | Alliance |
02.04.2024 16:51 | SAR | Result of WRAP Retail Offer | RNS |
02.04.2024 07:00 | SAR | Increase in size of WRAP Retail Offer | RNS |
28.03.2024 13:44 | WSG, REAT, HOME | EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost | Alliance |
28.03.2024 07:02 | SAR | WRAP Retail Offer | RNS |
28.03.2024 07:01 | SAR | Equity Fundraise | RNS |
28.03.2024 07:00 | SAR | Sareum Half-Year Report | RNS |
15.03.2024 12:46 | SAR | Sareum Holdings touts new patent allowance for autoimmune therapy | Alliance |
15.03.2024 07:00 | SAR | New Patent Allowance | RNS |
12.03.2024 15:23 | SAR | Sareum shares slump on widened loss and funding talks | Alliance |
12.03.2024 13:30 | SAR | Notice of Interim Results and Trading Update | RNS |
15.02.2024 11:20 | SAR | Sareum hails safety profile for SDC-1801 after phase 1 trial | Alliance |
15.02.2024 10:52 | DSW, SAR, N4P | AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets | Alliance |
15.02.2024 07:00 | SAR | Update on SDC-1801 Clinical Trial Progress | RNS |
02.01.2024 10:05 | POS, SAR, LLAI | AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal | Alliance |
02.01.2024 09:31 | SAR | Sareum soars as partner agrees SRA737 licence with US biopharma firm | Alliance |
02.01.2024 07:00 | SAR | Development and commercialisation licence SRA737 | RNS |
14.12.2023 20:20 | CTL, DGI9, AWEM | EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer | Alliance |
14.12.2023 15:35 | SAR | Results of AGM | RNS |
14.12.2023 07:00 | SAR | Annual General Meeting Statement | RNS |
07.12.2023 14:31 | SAR, MVI, HE1 | UK shareholder meetings calendar - next 7 days | Alliance |
23.11.2023 14:28 | RGO, SAR | IN BRIEF: Sareum Holdings draws down on equity prepayment facility | Alliance |
23.11.2023 07:00 | SAR | Drawdown of Equity Prepayment Facility | RNS |
21.11.2023 07:00 | SAR | Notice of AGM, Annual Report and Accounts | RNS |
09.11.2023 13:47 | UOG, SAR, CNC | EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings | Alliance |
09.11.2023 07:00 | SAR | Initiation of food effects study for SDC-1801 | RNS |
08.11.2023 15:03 | SAR | Director Dealings | RNS |
03.11.2023 09:01 | SAR | Sareum says patent notice in Japan boosts confidence in SDC-1801 | Alliance |
03.11.2023 07:05 | SAR | Sareum enhances SDC-1801 patent protection | RNS |
02.11.2023 14:48 | SAR | Exercise of Share Options and Director Dealings | RNS |
09.10.2023 10:58 | SAR | Sareum says earnings down but product development going well | Alliance |
09.10.2023 07:00 | SAR | Final Results for the Year Ended 30 June 2023 | RNS |
03.10.2023 07:00 | SAR | Notice of Results and Investor Presentation | RNS |
06.09.2023 07:00 | SAR | Director's Dealing | RNS |
05.09.2023 07:00 | SAR | Director Dealing | RNS |
04.09.2023 09:18 | SAR | Sareum begins dosing participants in phase 1a trial for SDC-1801 | Alliance |
04.09.2023 07:00 | SAR | Dosing of first subjects in MAD Phase 1a trial | RNS |
16.08.2023 13:13 | SAR | Sareum flagship drug trial progressing well ahead of annual results | Alliance |
16.08.2023 07:00 | SAR | Update on financial and operational progress | RNS |
03.08.2023 14:16 | SAR | IN BRIEF: Sareum secures GBP5 million of funding from RiverFort Global | Alliance |
03.08.2023 07:00 | SAR | Equity Prepayment Facility of up to £5 million | RNS |
26.06.2023 17:33 | SAR, CHF, CNE | TRADING UPDATES: New patents for Sareum; Guanajuato hails assessment | Alliance |
26.06.2023 07:00 | SAR | Sareum Announces Two New Granted Patents | RNS |
06.06.2023 13:36 | SAR | IN BRIEF: Sareum doses first subjects in psoriasis drug trial | Alliance |
06.06.2023 07:00 | SAR | Dosing commences in Phase 1a trial of SDC-801 | RNS |
18.05.2023 14:31 | ARV, STB, CIC | TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect | Alliance |
18.05.2023 07:00 | SAR | Phase 1a clinical trial for SDC-1801 | RNS |